Current Report Filing (8-k)
February 15 2018 - 8:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 13, 2018
CELGENE
CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
ITEM 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS
OF CERTAIN OFFICERS.
|
On February 15, 2018, Celgene Corporation (the “Company”)
announced the election of John H. Weiland to its Board of Directors and as a member of the Audit Committee effective on February
13, 2018. Mr. Weiland has over 25 years in the healthcare industry and was most recently the President and Chief Operating Officer
of C. R. Bard, Inc., with worldwide responsibility for all of Bard's business operations prior to it being acquired by Becton,
Dickinson and Company in December 2017. As a member of the Company’s Board of Directors, Mr. Weiland will receive an annual
fee of $75,000. In addition, under the Company’s 2017 Stock Incentive Plan, on February 13, 2018, the Company granted to
Mr. Weiland a non-qualified option to purchase 10,000 shares of the Company’s common stock. The option will vest in four
equal annual installments commencing on the first anniversary of the date of grant.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
|
|
|
|
|
|
Date: February 15, 2018
|
By:
|
/s/ Peter N. Kellogg
|
|
|
|
Peter N. Kellogg
|
|
|
|
Executive Vice President
|
|
|
|
Chief Financial Officer
|
|
|
|
(principal financial and accounting officer)
|
|
|
|
|
|
EXHIBIT INDEX
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024